Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peptide Receptor Radionuclide Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchUnknownNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Large-scale testing (Phase 3)Looking for participantsNCT07185672
What this trial is testing

PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Neuroendocrine Tumor GEP Grade 1-3Neuroendocrine Gastroenteropancreatic Tumour
Tata Memorial Hospital 162
Large-scale testing (Phase 3)Study completedNCT01842165
What this trial is testing

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Jules Bordet Institute 37
Not applicableStudy completedNCT05537675
What this trial is testing

Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction

Who this might be right for
Refractory Meningioma
Central Hospital, Nancy, France 20
Very early researchStudy completedNCT03197012
What this trial is testing

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Who this might be right for
Neuroendocrine Tumor
Thomas Hope 10
Not applicableLooking for participantsNCT04090034
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Testing effectiveness (Phase 2)Study completedNCT02736500
What this trial is testing

Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsGastro Entero Pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 39
Not applicableEnded earlyNCT02788578
What this trial is testing

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumours
Ipsen 40
Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84
Post-approval studies (Phase 4)Looking for participantsNCT06016855
What this trial is testing

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Digestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more
Vanderbilt-Ingram Cancer Center 6
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Testing effectiveness (Phase 2)Active Not RecruitingNCT02754297
What this trial is testing

Personalized PRRT of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorCarcinoma, Neuroendocrine
CHU de Quebec-Universite Laval 275
Not applicableNot Yet RecruitingNCT07538791
What this trial is testing

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)

Who this might be right for
PheochromocytomasParagangliomas
Azienda USL Reggio Emilia - IRCCS 210
Testing effectiveness (Phase 2)Looking for participantsNCT04939610
What this trial is testing

177Lu-FAP-2286 in Advanced Solid Tumors

Who this might be right for
Solid Tumor
Novartis Pharmaceuticals 222
Not applicableUnknownNCT04790708
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

Who this might be right for
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy (PRRT)
University Hospital of Ferrara 250
Not applicableStudy completedNCT07653126
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 117
Large-scale testing (Phase 3)Active Not RecruitingNCT03049189
What this trial is testing

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 324
Very early researchEnded earlyNCT03724409
What this trial is testing

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Who this might be right for
Neuroendocrine Tumors
Sandeep Laroia 3
Testing effectiveness (Phase 2)Study completedNCT03457948
What this trial is testing

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Who this might be right for
Metastatic Malignant Neoplasm in the LiverNeuroendocrine Neoplasm
Nicholas Fidelman, MD 32
Next Page